Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Zalicus Inc (NASDAQ:ZLCS), VIVUS, Inc. (NASDAQ:VVUS), Hologic, Inc. (NASDAQ:HOLX), NeoStem Inc (NASDAQ:NBS)
Zalicus Inc (NASDAQ:ZLCS) managed to keep its fall at -11.32% on above-normal volume of 3.05M shares. The stock settled at $5.64 after floating in a range of $5.31 to $6.25. Its latest price has reached market capitalization of $126.79 million. Its 52-week range has been $2.58 to $8.28. Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of novel treatments for patients suffering from pain.
Has ZLCS Found The Bottom and Ready To Move Up? Find Out Here
VIVUS, Inc. (NASDAQ:VVUS) traded up on a volume of 3.04 million, higher/ than its standard daily volume. Shares have gained 0.09% to $11.06. Over the last twelve months, the stock has lost-37.9% and faced a worst price of $9.11. VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health.
For How Long VVUS’s Gloss will Attract Investors? Find out via this report
Hologic, Inc. (NASDAQ:HOLX) settled -0.53% lower at $20.75 on below -normal volume of 3M shares during the last trading day. The stock has its 12-month high at $23.96 and 52-week low price was $18.45. It traded in a range of $20.66 to $21.03 during the last trading day. Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for women.
Will HOLX Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, NeoStem Inc (NASDAQ:NBS) was down on high volume, trading at a volume of 2.84M versus its average daily volume of 379,505.00 shares. At $7.09, the stock has attained market capitalization of 144.19 million. NeoStem, Inc. engages in the development of proprietary cell therapy products. It is involved in the manufacture of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services.
Why Should Investors Buy NBS After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)